SRC: Regulation, role in human carcinogenesis and pharmacological inhibitors

Current Pharmaceutical Design

Volumn 10, Issue 15, 2004, Pages 1745-1756

  Tsygankov, Alexander Y ^a   Shore, S K ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Inhibitor; Protein tyrosine kinase; Solid tumor; Src; Transformation

Indexed keywords

2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; 6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ADENOSINE TRIPHOSPHATE; BOSUTINIB; CGP 77675; ERBSTATIN; GENISTEIN; HERBIMYCIN A; IMATINIB; NAPHTHYRIDINE DERIVATIVE; OXINDOLE; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRAZOLOPYRIMIDINE DERIVATIVE; PYRIMIDINONE DERIVATIVE; PYRROLOPYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; TYROSINE KINASE RECEPTOR; TYRPHOSTIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CARCINOGENESIS; CELL DEATH; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DRUG DESIGN; DRUG EFFICACY; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; VIRUS GENE;

ANIMALS; ENZYME INHIBITORS; HUMANS; NEOPLASMS; SRC-FAMILY KINASES;

EID: 2442623056     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043384457     Document Type: Review

References (261)

1. Bjorge JD, Jakymiw A, Fujita DJ. Selected glimpses into the activation and function of src kinase. Oncogene 2000; 19: 5620-35.
2. Irby RB, Yeatman TJ. Role of src expression and activation in human cancer. Oncogene 2000; 19: 5636-42.
3. Bolen JB. Nonreceptor tyrosine protein kinases. Oncogene 1993; 8: 2025-31.
4. Tsygankov A, Bolen J. The Src family of tyrosine protein kinases in hemopoietic signal transduction. Stem Cells 1993; 11: 371-80.
5. Resh MD. Myristylation and palmitylation of SRC family members - The fats of the matter. Cell 1994; 76: 411-3.
6. Silverman L, Sudol M, Resh MD. Members of the Src family of nonreceptor tyrosine kinases share a common mechanism for membrane binding. Cell Growth Differ 1993; 4: 475-82.
7. Ley SC, Marsh M, Bebbington CR, Proudfoot K, Jordan P. Distinct intracellular localization of Lck and Fyn protein tyrosine kinases in human T lymphocytes. J Cell Biol 1994; 125: 639-49.
8. Pellman D, Garber EA, Cross FR, Hanafusa H. An N-terminal peptide from p60src can direct myristylation and plasma membrane localization when fused to heterologous proteins. Nature 1985; 314: 374-7.
9. Marchildon GA, Casnellie JE, Walsh KA, Krebs EG. Covalently bound myristate in a lymphoma tyrosine protein kinase. Proc Natl Acad Sci USA 1984; 81: 7679-82.
10. Peters DJ, McGrew BR, Perron DC, Liptak LM, Laudano AP. In vivo phosphorylation and membrane association of the fyn protooncogene product in IM-9 human lymphoblasts. Oncogene 1990; 5: 1313-9.
11. Shenoy-Scaria AM, Gauen LK, Kwong J, Shaw AS, Lublin DM. Palmitylation of an amino-terminal cysteine motif of protein tyrosine kinases p56lck and p59fyn mediates interaction with glycosyl-phosphatidylinositol-anchored proteins. Mol Cell Biol 1993; 13: 6385-92.
12. Paige LA, Nadler MJS, Harrison ML, Cassady JM, Geahlen RL. Reversible Palmitoylation of the Protein-Tyrosine Kinase p56(lck). J Biol Chem 1993; 268: 8669-74.
13. Koegl M, Zlatkine P, Ley SC, Courtneidge SA, Magee AI. Palmitoylation of multiple Src-family kinases at a homologous N-terminal motif. Biochem J 1994; 303: 749-53.
14. Cooke MP, Abraham KM, Forbush KA, Permutter RM. Regulation of T cell receptor signaling by a src family protein-tyrosine kinase (p59fyn). Cell 1991; 65: 281-91.
15. lck with CD4 in antigen-specific signal transduction in T cells. Cell 1991; 64: 511-20.
16. Abraham N, Miceli MC, Parries JR, Veillette A. Enhancement of T-cell responsiveness by the lymphocyte-specific tyrosine protein kinase p56lck. Nature 1991; 350: 62-6.
17. Appleby MW, Gross JA, Cooke MP, Levin SD, Qian X, Perlmutter RM. Defective T-cell receptor signaling in mice lacking the thymic isoform of p59fyn. Cell 1992; 70: 751-63.
18. Karnitz L, Sutor SL, Torigoe T, Reed JC, Bell MP, Mckean DJ, et al. Effects of p56lck deficiency on the growth and cytolytic effector function of an interleukin-2-dependent cytotoxic T-cell line. Mol Cell Biol 1992; 12: 4521-30.
19. Stein PL, Lee HM, Rich S, Soriano P. pp59(fyn) mutant mice display differential signaling in thymocytes and peripheral T-cells. Cell 1992; 70: 741-50.
20. Straus DB, Weiss A. Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor. Cell 1992; 70: 585-93.
21. Cone JC, Lu Y, Trevillyan JM, Bjorndahl JM, Phillips CA. Association of the p56lck protein tyrosine kinase with the Fc gamma RIIIA/CD16 complex in human natural killer cells. Eur J Immunol 1993; 23: 2488-97.
22. Takata M, Sabe H, Hata A, Inazu T, Homma Y, Nukada T, et al. Tyrosine kinases Lyn and Syk regulate B cell receptor-coupled Ca2+ mobilization through distinct pathways. EMBO J 1994; 13: 1341-9.
23. Tsygankov AY, Kim HW, Pratt JC, Spana C, Class K, Gaulton GN, et al. Diminished tyrosine protein kinase activity in T cells unresponsive to TCR stimulation. J Leuk Biol 1994; 55: 289-98.
24. Beaty CD, Franklin TL, Uehara Y, Wilson CB. Lipopolysaccharide-induced cytokine production in human monocytes: role of tyrosine phosphorylation in transmembrane signal transduction. Eur J Immunol 1994; 24: 1278-84.
25. Raab M, Cai YC, Bunnell SC, Heyeck SD, Berg LJ, Rudd CE. p56Lck and p59Fyn regulate CD28 binding to phosphatidylinositol 3-kinase, growth factor receptor-bound protein GRB-2, and T cell-specific protein-tyrosine kinase ITK: implications for T-cell costimulation. Proc Natl Acad Sci USA 1995; 92: 8891-5.
26. Iwashima M, Irving BA, van Oers NS, Chan AC, Weiss A. Sequential interactions of the TCR with two distinct cytoplasmic tyrosine kinases. Science 1994; 263: 1136-9.
27. Flaswinkel H, Reth M. Dual role of the tyrosine activation motif of the Ig-alpha protein during signal transduction via the B cell antigen receptor. EMBO J 1994; 13: 83-9.
28. Bewarder N, Weinrich V, Budde P, Hartmann D, Flaswinkel H, Reth M, et al. In vivo and in vitro specificity of protein tyrosine kinases for immunoglobulin G receptor (FcgammaRII) phosphorylation. Mol Cell Biol 1996; 16: 4735-43.
29. Schmitz R, Baumann G, Gram H. Catalytic specificity of phosphotyrosine kinases Blk, Lyn, c-Src and Syk as assessed by phage display. J Mol Biol 1996; 260: 664-77.
30. lck. Proc Natl Acad Sci USA 1991; 88: 1996-2000.
31. Torigoe T, O-Connor R, Fagard R, Fischer S, Santoli D, Reed JC. Regulation of SRC-family protein tyrosine kinases by interleukins, IL-2, and IL-3. Leukemia 1992; 6: 94S-97S.
32. lyn with the interleukin 2 receptor: Implications for redundancy and pleiotropism in cytokine signal transduction. Proc Natl Acad Sci USA 1993; 90: 4201-5.
33. Taichman R, Merida I, Torigoe T, Gaulton GN, Reed JC. Evidence That Protein Tyrosine Kinase p56-Lck Regulates the Activity of Phosphatidylinositol-3′-kinase in Interleukin-2-Dependent T-Cells. J Biol Chem 1993; 268: 20031-6.
34. Shibuya H, Kohu K, Yamada K, Barsoumian EL, Perlmutter RM, Taniguchi T. Functional dissection of p56(lck), a protein tyrosine kinase which mediates interleukin-2-induced activation of the c-fos gene. Mol Cell Biol 1994; 14: 5812-9.
35. Miyazaki T, Liu ZJ, Kawahara A, Minami Y, Yamada K, Tsujimoto Y, et al. Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation. Cell 1995; 81: 223-31.
36. Anderson SM, Jorgensen B. Activation of src-related tyrosine kinases by IL-3. J Immunol 1995; 155: 1660-70.
37. Hallek M, Neumann C, Schaffer M, Danhauser-Riedl S, von Bubnoff N, de Vos G, et al. Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines. Exp Hematol 1997; 25: 1367-77.
38. Chaturvedi P, Reddy MV, Reddy EP. Src kinases and not JAKs activate STATs during IL-3 induced myeloid cell proliferation. Oncogene 1998; 16: 1749-58.
39. Fuhrer DK, Yang YC. Complex formation of JAK2 with PP2A, P13K, and Yes in response to the hematopoietic cytokine interleukin-11. Biochem Biophys Res Commun 1996; 224: 289-96.
40. Uddin S, Sher DA, Alsayed Y, Pons S, Colamonici OR, Fish EN, et al. Interaction of p59fyn with interferon-activated Jak kinases. Biochem Biophys Res Commun 1997; 235: 83-8.
41. Sayeski PP, Ali MS, Hawks K, Frank SJ, Bernstein KE. The angiotensin II-dependent association of Jak2 and c-Src requires the N-terminus of Jak2 and the SH2 domain of c-Src. Circ Res 1999; 84: 1332-8.
42. Courtneidge SA, Dhand R, Pilat D, Twamley GM, Waterfield MD, Roussel MF. Activation of Src family kinases by colony stimulating factor-1, and their association with its receptor. EMBO J 1993; 12: 943-50.
43. Filhol O, Chambaz EM, Gill GN, Cochet C. Epidermal growth factor stimulates a protein tyrosine kinase which is separable from the epidermal growth factor receptor. J Biol Chem 1993; 268: 26978-82.
44. Larose L, Gish G, Shoelson S, Pawson T. Identification of residues in the beta platelet-derived growth factor receptor that confer specificity for binding to phospholipase C-gamma-1. Oncogene 1993; 8: 2493-9.
45. Mori S, Ronnstrand L, Yokote K, Engstrom A, Courtneidge SA, Claesson-Welsh L, et al. Identification of two juxtamembrane autophosphorylation sites in the PDGF beta-receptor; involvement in the interaction with Src family tyrosine kinases. EMBO J 1993; 12: 2257-64.
46. Twamley-Stein GM, Pepperkok R, Ansorge W, Courtneidge SA. The Src family tyrosine kinases are required for platelet-derived growth factor-mediated signal transduction in NIH 3T3 cells. Proc Natl Acad Sci USA 1993; 90: 7696-700.
47. Landgren E, Blume-Jensen P, Courtneidge SA, Claesson-Welsh L. Fibroblast growth factor receptor-1 regulation of Src family kinases. Oncogene 1995; 10: 2027-35.
48. Clark EA, Brugge JS. Redistribution of activated pp60c-src to integrin-dependent cytoskeletal complexes in thrombin-stimulated platelets. Mol Cell Biol 1993; 13: 1863-71.
49. Hamaguchi M, Xiao H, Uehara Y, Ohnishi Y, Nagai Y. Herbimycin-A inhibits the association of p60(v-src) with the cytoskeletal structure and with phosphatidylinositol-3′ kinase. Oncogene 1993; 8: 559-64.
50. Fox JEB, Lipfert L, Clark EA, Reynolds CC, Austin CD, Brugge JS. On the role of the platelet membrane skeleton in mediating signal transduction - Association of GP-IIb-IIIa, pp60(c-src), pp62(c-yes), and the p21(ras) GTPase-activating protein with the membrane skeleton. J Biol Chem 1993; 268: 25973-84.
51. Weng Z, Taylor JA, Turner CE, Brugge JS, Seidel-Dugan C. Detection of Src homology 3-binding proteins, including paxillin, in normal and v-Src-transformed Balb/c 3T3 cells. J Biol Chem 1993; 268: 14956-63.
52. Minoguchi K, Kihara H, Nishikata H, Hamawy MM, Siraganian RP. Src family tyrosine kinase Lyn binds several proteins including paxillin in rat basophilic leukemia cells. Mol Immunol 1994; 31: 519-29.
53. Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, Parsons JT. Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol 1994; 14: 1680-8.
54. Xing Z, Chen HC, Nowlen JK, Taylor SJ, Shalloway D, Guan JL. Direct interaction of v-Src with the focal adhesion kinase mediated by the Src SH2 domain. Mol Biol Cell 1994; 5: 413-21.
55. Kaplan KB, Bibbins KB, Swedlow JR, Arnaud M, Morgan DO, Varmus HE. Association of the amino-terminal half of c-Src with focal adhesions alters their properties and is regulated by phosphorylation of tyrosine 527. EMBO J 1994; 13: 4745-56.
56. Thomas SM, Soriano P, Imamoto A. Specific and redundant roles of Src and Fyn in organizing the cytoskeleton. Nature 1995; 376: 267-71.
57. Cobb BS, Schaller MD, Len TH, Parsons JT. Stable association of pp60src and pp59fyn with the focal adhesion-associated protein tyrosine kinase, pp125FAK. Mol Cell Biol 1994; 14: 147-55.
58. Eide BL, Turck CW, Escobedo JA. Identification of Tyr-397 as the primary site of tyrosine phosphorylation and pp60src association in the focal adhesion kinase, pp125FAK. Mol Cell Biol 1995; 15: 2819-27.
59. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991; 64: 693-702.
60. Boyce BF, Yoneda T, Lowe C, Soriano P, Mundy GR. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 1992; 90: 1622-7.
61. Molina TJ, Kishihara K, Siderovski DP, Van Ewijk W, Narendran A, Timms E, et al. Profound block in thymocyte development in mice lacking P56LCK. Nature 1992; 357: 161-4.
62. Molina TJ, Bachmann MF, Kundig TM, Zinkernagel RM, Mak TW. Peripheral T-cells in mice lacking P56(lck) do not express significant antiviral effector functions. J Immunol 1993; 151: 699-706.
63. Wen T, Zhang L, Kung SK, Molina TJ, Miller RG, Mak TW. Allo-skin graft rejection, tumor rejection and natural killer activity in mice lacking p56lck. Eur J Immunol 1995; 25: 3155-9.
64. Anderson SJ, Levin SD, Perlmutter RM. Protein tyrosine kinase p56(lck) controls allelic exclusion of T-cell receptor beta-chain genes. Nature 1993; 365: 552-4.
65. Mombaerts P, Anderson SJ, Perlmutter RM, Mak TW, Tonegawa S. An activated lck transgene promotes thymocyte development in RAG-1 mutant mice. Immunity 1994; 1: 261-7.
66. Grant SG, O'Dell TJ, Karl KA, Stein PL, Soriano P, Kandel ER. Impaired long-term potentiation, spatial learning, and hippocampal development in fyn mutant mice. Science 1992; 258: 1903-10.
67. Umemori H, Sato S, Yagi T, Aizawa S, Yamamoto T. Initial events of myelination involve Fyn tyrosine kinase signalling. Nature 1994; 367: 572-6.
68. Miyakawa T, Yagi T, Watanabe S, Niki H. Increased fearfulness of Fyn tyrosine kinase deficient mice. Mol Brain Res 1994; 27: 179-82.
69. Beggs HE, Soriano P, Maness PF. NCAM-dependent neurite outgrowth is inhibited in neurons from Fyn-minus mice. J Cell Biol 1994; 127: 825-33.
70. Calautti E, Missero C, Stein PL, Ezzell RM, Dotto GP. fyn tyrosine kinase is involved in keratinocyte differentiation control. Genes Develop 1995; 9: 2279-91.
71. Hibbs ML, Tarlinton DM, Armes J, Grail D, Hodgson G, Maglitto R, et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 1995; 83: 301-11.
72. Nishizumi H, Taniuchi I, Yamanashi Y, Kitamura D, Ilic D, Mori S, et al. Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice. Immunity 1995; 3: 549-60.
73. Lowell CA, Soriano P. Knockouts of Src-family kinases: stiff bones, wimpy T cells, and bad memories. Genes Develop 1996; 10: 1845-57.
74. Lowell CA, Niwa M, Soriano P, Varmus HE. Deficiency of the Hck and Src tyrosine kinases results in extreme levels of extramedullary hematopoiesis. Blood 1996; 87: 1780-92.
75. Vanoers NSC, Lowinkropf B, Finlay D, Connolly K, Weiss A. Alpha-beta T cell development is abolished in mice lacking both Lck and Fyn protein tyrosine kinases. Immunity 1996; 5: 429-36.
76. Lowell CA, Soriano P, Varmus HE. Functional overlap in the Src gene family - inactivation of Hck and Fgr impairs natural immunity. Gene Develop 1994; 8: 387-98.
77. Lowell CA, Fumagalli L, Berton G. Deficiency of Src family kinases p59/61hck and p5gc-fgr results in defective adhesion-dependent neutrophil functions. J Cell Biol 1996; 133: 895-910.
78. Meng F, Lowell CA. A beta 1 integrin signaling pathway involving Src-family kinases, Cbl and PI-3 kinase is required for macrophage spreading and migration. EMBO J 1998; 17: 4391-403.
79. Cooper JA, MacAuley A. Potential positive and negative autoregulation of p60c-src by intermolecular autophosphorylation. Proc Natl Acad Sci USA 1988; 85: 4232-6.
80. Barker SC, Kassel DB, Weigl D, Huang X, Luther MA, Knight WB. Characterization of pp60c-src tyrosine kinase activities using a continuous assay: autoactivation of the enzyme is an intermolecular autophosphorylation process. Biochemistry 1995; 34: 14843-51.
81. Sotirellis N, Johnson TM, Hibbs ML, Stanley IJ, Stanley E, Dunn AR, et al. Autophosphorylation induces autoactivation and a decrease in the Src homology 2 domain accessibility of the Lyn protein kinase. J Biol Chem 1995; 270: 29773-80.
82. Zhou S, Carraway KLr, Eck MJ, Harrison SC, Feldman RA, Mohammadi M, et al. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 1995; 373: 536-9.
83. Yamaguchi H, Hendrickson WA. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 1996; 384: 484-9.
84. Xu W, Harrison SC, Eck MJ. Three-dimensional structure of the tyrosine kinase c-Src. Nature 1997; 385: 595-602.
85. Williams JC, Weijland A, Gonfloni S, Thompson A, Courtneidge SA, Superti-Furga G, et al. The 2.35 A crystal structure of the inactivated form of chicken Src: a dynamic molecule with multiple regulatory interactions. J Mol Biol 1997; 274: 757-75.
86. Sicheri F, Moarefi I, Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature 1997; 385: 602-9.
87. Xu W, Doshi A, Lei M, Eck MJ, Harrison SC. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell 1999; 3: 629-38.
88. Schindler T, Sicheri F, Pico A, Gazit A, Levitzki A, Kuriyan J. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol Cell 1999; 3: 639-48.
89. Roussel RR, Brodeur SR, Shalloway D, Laudano AP. Selective binding of activated pp60c-src by an immobilized synthetic phosphopeptide modeled on the carboxyl terminus of pp60c-src. Proc Natl Acad Sci USA 1991; 88: 10696-700.
90. Liu X, Brodeur SR, Gish G, Songyang Z, Cantley LC, Laudano AP, et al. Regulation of c-Src tyrosine kinase activity by the Src SH2 domain. Oncogene 1993; 8: 1119-26.
91. Amrein KE, Panholzer B, Flint NA, Bannwarth W, Burn P. The Src homology 2 domain of the protein-tyrosine kinase p56lck mediates both intermolecular and intramolecular interactions. Proc Natl Acad Sci USA 1993; 90: 10285-9.
92. Weijland A, Williams JC, Neubauer G, Courtneidge SA, Wierenga RK, Superti-Furga G. Src regulated by C-terminal phosphorylation is monomeric. Proc Natl Acad Sci USA 1997; 94: 3590-5.
93. Gonfloni S, Frischknecht F, Way M, Superti-Furga G. Leucine 255 of Src couples intramolecular interactions to inhibition of catalysis. Nat Struct Biol 1999; 6: 760-4.
94. Cartwright CA, Eckhart W, Simon S, Kaplan PL. Cell transformation by pp60c-src mutated in the carboxy-terminal regulatory domain. Cell 1987; 49: 83-91.
95. Reynolds AB, Vila J, Lansing TJ, Potts WM, Weber MJ, Parsons JT. Activation of the oncogenic potential of the avian cellular src protein by specific structural alteration of the carboxy terminus. EMBO J 1987; 6: 2359-64.
96. Marth JD, Cooper JA, King CS, Ziegler SF, Tinker DA, Overell RW, et al. Neoplastic transformation induced by an activated lymphocyte-specific protein tyrosine kinase (pp56lck). Mol Cell Biol 1988; 8: 540-50.
97. Kawakami T, Kawakami Y, Aaronson SA, Robbins KC. Acquisition of transforming properties by FYN, a normal SRC-related human gene. Proc Natl Acad Sci USA 1988; 85: 3870-4.
98. Hirai H, Varmus HE. Mutations in src homology regions 2 and 3 of activated chicken c-src that result in preferential transformation of mouse or chicken cells. Proc Natl Acad Sci USA 1990; 87: 8592-6.
99. Reynolds PJ, Hurley TR, Sefton BM. Functional analysis of the SH2 and SH3 domains of the lck tyrosine protein kinase. Oncogene 1992; 7: 1949-55.
100. Veillette A, Caron L, Fournel M, Pawson T. Regulation of the enzymatic function of the lymphocyte-specific tyrosine protein kinase p56lck by the non-catalytic SH2 and SH3 domains. Oncogene 1992; 7: 971-80.
101. Seideldugan C, Meyer BE, Thomas SM, Brugge JS. Effects of SH2 and SH3 deletions on the functional activities of wild-type and transforming variants of c-Src. Mol Cell Biol 1992; 12: 1835-45.
102. Thomas JE, Soriano P, Brugge JS. Phosphorylation of c-Src on tyrosine 527 by another protein tyrosine kinase. Science 1991; 254: 568-71.
103. Okada M, Nada S, Yamanashi Y, Yamamoto T, Nakagawa H. CSK: a protein-tyrosine kinase involved in regulation of Src family kinases. J Biol Chem 1991; 266: 24249-52.
104. Bergman M, Mustelin T, Oetken C, Partanen J, Flint NA, Amrein KE, et al. The human p50csk tyrosine kinase phosphorylates p56lck at Tyr-505 and down regulates its catalytic activity. EMBO J 1992; 11: 2919-24.
105. Sabe H, Okada M, Nakagawa H, Hanafusa H. Activation of c-Src in cells bearing v-Crk and its suppression by Csk. Mol Cell Biol 1992; 12: 4706-13.
106. Nada S, Yagi T, Takeda H, Tokunaga T, Nakagawa H, Ikawa Y, et al. Constitutive activation of Src family kinases in mouse embryos that lack Csk. Cell 1993; 73: 1125-35.
107. Takeuchi M, Kuramochi S, Fusaki N, Nada S, Kawamura-Tsuzuku J, Matsuda S, et al. Functional and physical interaction of protein-tyrosine kinases Fyn and Csk in the T-cell signaling system. J Biol Chem 1993; 268: 27413-9.
108. Chow LM, Fournel M, Davidson D, Veillette A. Negative regulation of T-cell receptor signalling by tyrosine protein kinase p50csk. Nature 1993; 365: 156-60.
109. Superti-Furga G, Fumagalli S, Koegl M, Courtneidge SA, Draetta G. Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src. EMBO J 1993; 12: 2625-34.
110. Mustelin T, Coggeshall KM, Altman A. Rapid activation of the T-cell tyrosine protein kinase pp56lck by the CD45 phosphotyrosine phosphatase. Proc Natl Acad Sci USA 1989; 86: 6302-6.
111. Mustelin T, Altman A. Dephosphorylation and activation of the T cell tyrosine kinase pp56lck by the leukocyte common antigen (CD45). Oncogene 1990; 5: 809-13.
112. Mustelin T, Pessa-Morikawa T, Autero M, Gassmann M, Andersson LC, Gahmberg CG, et al. Regulation of the p59fyn protein tyrosine kinase by the CD45 phosphotyrosine phosphatase. Eur J Immunol 1992; 22: 1173-8.
113. Shiroo M, Goff L, Biffen M, Shivnan E, Alexander D. CD45 tyrosine phosphatase-activated p59fyn couples the T cell antigen receptor to pathways of diacylglycerol production, protein kinase C activation and calcium influx. EMBO J 1992; 11: 4887-97.
114. Hurley TR, Hyman R, Sefton BM. Differential effects of expression of the CD45 tyrosine protein phosphatase on the tyrosine phosphorylation of the lck, tyn, and c-src tyrosine protein kinases. Mol Cell Biol 1993; 13: 1651-6.
115. Sieh M, Bolen JB, Weiss A. CD45 specifically modulates binding of Lck to a phosphopeptide encompassing the negative regulatory tyrosine of Lck. EMBO J 1993; 12: 315-21.
116. Biffen M, Mcmichaelphillips D, Larson T, Venkitaraman A, Alexander D. The CD45 tyrosine phosphatase regulates specific pools of antigen receptor-associated p59(Fyn) and CD4-associated p56(Lck) tyrosine kinases in human T-cells. EMBO J 1994; 13: 1920-9.
117. Zheng XM, Wang Y, Pallen CJ. Cell transformation and activation of pp60c-src by overexpression of a protein tyrosine phosphatase. Nature 1992; 359: 336-9.
118. Fang KS, Sabe H, Saito H, Hanafusa H. Comparative study of three protein-tyrosine phosphatases. Chicken protein-tyrosine phosphatase lambda dephosphorylates c-Src tyrosine 527. J Biol Chem 1994; 269: 20194-200.
119. Harder KW, Moller NP, Peacock JW, Jirik FR. Protein-tyrosine phosphatase alpha regulates Src family kinases and alters cell-substratum adhesion. J Biol Chem 1998; 273: 31890-900.
120. Pani G, Fischer KD, Mlinaricrascan I, Siminovitch KA. Signaling capacity of the T cell antigen receptor is negatively regulated by the PTP1C tyrosine phosphatase. J Exp Med 1996; 184: 839-52.
121. Raab M, Rudd CE. Hematopoietic cell phosphatase (HCP) regulates p56LCK phosphorylation and ZAP-70 binding to T cell receptor zeta chain. Biochem Biophys Res Commun 1996; 222: 50-7.
122. Plas DR, Johnson R, Pingel JT, Matthews RJ, Dalton M, Roy G, et al. Direct regulation of ZAP-70 by SHP-1 in T cell antigen receptor signaling. Science 1996; 272: 1173-6.
123. Cloutier JF, Veillette A. Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase. J Exp Med 1999; 189: 111-21.
124. Alonso G, Koegl M, Mazurenko N, Courtneidge SA. Sequence requirements for binding of Src family tyrosine kinases to activated growth factor receptors. J Biol Chem 1995; 270: 9840-8.
125. Burnham MR, Bruce-Staskal PJ, Harte MT, Weidow CL, Ma A, Weed SA, et al. Regulation of c-SRC activity and function by the adapter protein CAS. Mol Cell Biol 2000; 20: 5865-78.
126. Alexandropoulos K, Baltimore D. Coordinate activation of c-Src by SH3- and SH2-binding sites on a novel p130Cas-related protein, Sin. Genes Dev 1996; 10: 1341-55.
127. Moarefi I, LaFevre-Bernt M, Sicheri F, Huse M, Lee CH, Kuriyan J, et al. Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature 1997; 385: 650-3.
128. Briggs SD, Sharkey M, Stevenson M, Smithgall TE. SH3-mediated Hck tyrosine kinase activation and fibroblast transformation by the Nef protein of HIV-1. J Biol Chem 1997: 272: 17899-902.
129. Veillette A, Horak ID, Horak EM, Bookman MA, Bolen JB. Alterations of the lymphocyte-specific protein tyrosine kinase (p56lck) during T-cell activation. Mol Cell Biol 1988; 8: 4353-61.
130. Veillette A, Horak ID, Bolen JB. Post-translational alterations of the tyrosine kinase p56lck in response to activators of protein kinase C. Oncogene Res 1988; 2: 385-401.
131. Luo KX, Sefton BM. Analysis of the sites in p56lck whose phosphorylation is induced by tetradecanoyl phorbol acetate. Oncogene 1990; 5: 803-8.
132. Winkler DG, Park I, Kim T, Payne NS, Walsh CT, Strominger JL, et al. Phosphorylation of Ser-42 and Ser-59 in the N-terminal region of the tyrosine kinase p56(lck). Proc Natl Acad Sci USA 1993; 90: 5176-80.
133. Watts JD, Sanghera JS, Pelech SL, Aebersold R. Phosphorylation of Serine-59 of p56(lck) in activated T-cells. J Biol Chem 1993; 268: 23275-82.
134. Watts JD, Welham MJ, Kalt L, Schrader JW, Aebersold R. IL-2 Stimulation of T-lymphocytes induces sequential activation of mitogen-activated protein kinases and phosphorylation of p56(lck) at Serine-59. J Immunol 1993; 151: 6862-71.
135. Schmitt JM, Stork PJ. PKA phosphorylation of Src mediates cAMP's inhibition of cell growth via Rap1. Mol Cell 2002; 9: 85-94.
136. Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau RW, et al. Activating SRC mutation in a subset of advanced human colon cancers. Nature Genet 1999; 21: 187-90.
137. Wang P, Fromowitz F, Koslow M, Hagag N, Johnson B, Viola M. c-src structure in human cancers with elevated pp60c-src activity. Br J Cancer 1991; 64: 531-3.
138. Daigo Y, Furukawa Y, Kawasoe T, Ishiguro H, Fujita M, Sugai S, et al. Absence of genetic alteration at codon 531 of the human c-src gene in 479 advanced colorectal cancers from Japanese and Caucasian patients. Cancer Res 1999; 59: 4222-4.
139. Laghi L, Bianchi P, Orbetegli O, Gennari L, Roncalli M, Malesci A. Lack of mutation at codon 531 of SRC in advanced colorectal cancers from Italian patients. Br J Cancer 2001; 84: 196-8.
140. Wang NM, Yeh KT, Tsai CH, Chen SJ, Chang JG. No evidence of correlation between mutation at codon 531 of src and the risk of colon cancer in Chinese. Cancer Lett 2000; 150: 201-4.
141. Biscardi JS, Tice DA, Parsons SJ. c-Src, receptor tyrosine kinases, and human cancer. Adv Cancer Res 1999; 76: 61-119.
142. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
143. Dehm S, Senger MA, Bonham K. SRC transcriptional activation in a subset of human colon cancer cell lines. FEBS Lett 2001; 487: 367-71.
144. Lundy J, Chen J, Wang P, Fromowitz F, Schuss A, Lynch S, et al. Phenotypic and genetic alterations in pre-cancerous cells in the colon. Anticancer Res 1988; 8: 1005-13.
145. Bolen JB, Veillette A, Schwartz AM, DeSeau V, Rosen N. Activation of pp60c-src protein kinase activity in human colon carcinoma. Proc Natl Acad Sci USA 1987; 84: 2251-5.
146. Bolen JB, Veillette A, Schwartz AM, Descau V, Rosen N. Analysis of pp60c-src in human colon carcinoma and normal human colon mucosal cells. Oncogene Res 1987; 1: 149-68.
147. Rosen N, Bolen JB, Schwartz AM, Cohen P, DeSeau V, Israel MA. Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. J Biol Chem 1986; 261: 13754-9.
148. Cartwright CA, Kamps MP, Meisler AI, Pipas JM, Eckhart W. pp60c-src activation in human colon carcinoma. J Clin Invest 1989; 83: 2025-33.
149. Cartwright CA, Meisler AI, Eckhart W. Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis. Proc Natl Acad Sci USA 1990; 87: 558-62.
150. Cartwright CA, Coad CA, Egbert BM. Elevated c-Src tyrosine kinase activity in premalignant epithelia of ulcerative colitis. J Clin Invest 1994; 93: 509-15.
151. Mao W, Irby R, Coppola D, Fu L, Wloch M, Turner J, et al. Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene 1997; 15: 3083-90.
152. Iravani S, Mao W, Fu L, Karl R, Yeatman T, Jove R, et al. Elevated c-Src protein expression is an early event in colonic neoplasia. Lab Invest 1998; 78: 365-71.
153. Termuhlen PM, Curley SA, Talamonti MS, Saboorian MH, Gallick GE. Site-specific differences in pp60c-src activity in human colorectal metastases. J Surg Res 1993; 54: 293-8.
154. Talamonti MS, Roh MS, Curley SA, Gallick GE. Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 1993; 91: 53-60.
155. Weber JR, Bell GM, Han MY, Pawson T, Imboden JB. Association of the tyrosine kinase Lck with phospholipase C-γ1 after stimulation of the T-cell antigen receptor. J Exp Med 1992; 176: 373-379.
156. Malek RL, Irby RB, Guo QM, Lee K, Wong S, He M, et al. Identification of Src transformation fingerprint in human colon cancer. Oncogene 2002; 21: 7256-65.
157. Rustgi AK. c-src tyrosine kinase activity: a marker of dysplasia in ulcerative colitis. Gastroenterology 1994; 107: 1565-6.
158. Guy CT, Muthuswamy SK, Cardiff RD, Soriano P, Muller WJ. Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. Genes Dev 1994; 8: 23-32.
159. Muthuswamy SK, Gilman M, Brugge JS. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol 1999; 19: 6845-57.
160. Webster MA, Cardiff RD, Muller WJ. Induction of mammary epithelial hyperplasias and mammary tumors in transgenic mice expressing a marine mammary tumor virus/activated c-src fusion gene. Proc Natl Acad Sci USA 1995; 92: 7849-53.
161. Bjorge JD, Pang A, Fujita DJ. Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines. J Biol Chem 2000; 275: 41439-46.
162. Belsches-Jablonski AP, Biscardi JS, Peavy DR, Tice DA, Romney DA, Parsons SJ. Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene 2001; 20: 1465-75.
163. Egan C, Pang A, Durda D, Cheng HC, Wang JH, Fujita DJ. Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530. Oncogene 1999; 18: 1227-37.
164. Hennipman A, van Oirschot BA, Smits J, Rijksen G, Staal GE. Tyrosine kinase activity in breast cancer, benign breast disease, and normal breast tissue. Cancer Res 1989; 49: 516-21.
165. Jacobs C, Rubsamen H. Expression of pp60c-src protein kinase in adult and fetal human tissue: high activities in some sarcomas and mammary carcinomas. Cancer Res 1983; 43: 1696-702.
166. Reissig D, Clement J, Sanger J, Berndt A, Kosmehl H, Bohmer FD. Elevated activity and expression of Src-family kinases in human breast carcinoma tissue versus matched non-tumor tissue. J Cancer Res Clin Oncol 2001; 127: 226-30.
167. Verbeck BS, Vroom TM, Adriaansen-Slot SS, Ottenhoff-Kalff AE, Geertzema JG, Hennipman A, et al. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 1996; 180: 383-8.
168. Bougeret C, Jiang S, Keydar I, Avraham H. Functional analysis of Csk and CHK kinases in breast cancer cells. J Biol Chem 2001; 276: 33711-20.
169. Benistant C, Bourgaux JF, Chapuis H, Mottet N, Roche S, Bali JP. The COOH-terminal Src kinase Csk is a tumor antigen in human carcinoma. Cancer Res 2001; 61: 1415-20.
170. Chackalaparampil I, Shalloway D. Altered phosphorylation and activation of pp60c-src during fibroblast mitosis. Cell 1988; 52: 801-10.
171. Kaplan KB, Swedlow JR, Varmus HE, Morgan DO. Association of p6Oc-src with endosomal membranes in mammalian fibroblasts. J Cell Biol 1992; 118: 321-33.
172. Lutz MP, Esser IB, Flossmann-Kast BB, Vogelmann R, Luhrs H, Friess H, et al. Overexpression and activation of the tyrosine kinase Src
173. MacMillan-Crow LA, Greendorfer JS, Vickers SM, Thompson JA. Tyrosine nitration of c-SRC tyrosine kinase in human pancreatic ductal adenocarcinoma. Arch Biochem Biophys 2000; 377: 350-6.
174. Flossmann-Kast BB, Jehle PM, Hoeflich A, Adler G, Lutz MP. Src stimulates insulin-like growth factor I (IGF-I)-dependent cell proliferation by increasing IGF-I receptor number in human pancreatic carcinoma cells. Cancer Res 1998; 58: 3551-4.
175. Masaki T, Okada M, Shiratori Y, Rengifo W, Matsumoto K, Maeda S, et al. pp60c-src activation in hepatocellular carcinoma of humans and LEC rats. Hepatology 1998; 27: 1257-64.
176. Masaki T, Okada M, Tokuda M, Shiratori Y, Hatase O, Shirai M, et al. Reduced C-terminal Src kinase (Csk) activities in hepatocellular carcinoma. Hepatology 1999; 29: 379-84.
177. Benistant C, Chapuis H, Mottet N, Noletti J, Crapez E, Bali JP, et al. Deregulation of the cytoplasmic tyrosine kinase cSrc: in the absence of a truncating mutation at codon 531 in human bladder carcinoma. Biochem Biophys Res Commun 2000; 273: 425-30.
178. Kumble S, Omary MB, Cartwright CA, Triadafilopoulos G. Src activation in malignant and premalignant epithelia of Barrett's esophagus. Gastroenterology 1997; 112: 348-56.
179. Takekura N, Yasui W, Yoshida K, Tsujino T, Nakayama H, Kameda T, et al. pp60c-src protein kinase activity in human gastric carcinomas. Int J Cancer 1990; 45: 847-51.
180. Bolen JB, Rosen N, Israel MA. Increased pp60c-src tyrosyl kinase activity in human neuroblastomas is associated with amino-terminal tyrosine phosphorylation of the src gene product. Proc Natl Acad Sci USA 1985; 82: 7275-9.
181. Bjelfman C, Hedborg F, Johansson I, Nordenskjold M, Pahlman S. Expression of the neuronal form of pp60c-src in neuroblastoma in relation to clinical stage and prognosis. Cancer Res 1990; 50: 6908-14.
182. Matsunaga T, Takahashi H, Ohnuma N, Tanabe M, Yoshida H, Iwai J, et al. Expression of N-myc and c-src protooncogenes correlating to the undifferentiated phenotype and prognosis of primary neuroblastomas. Cancer Res 1991; 51: 3148-52.
183. Veillette A, O'Shaughnessy J, Horak ID, Israel MA, Yee D, Rosen N, et al. Coordinate alteration of pp60c-src abundance and c-src RNA expression in human neuroblastoma variants. Oncogene 1989; 4: 421-7.
184. Matsunaga T, Shirasawa H, Enomoto H, Yoshida H, Iwai J, Tanabe M, et al. Neuronal src and trk a protooncogene expression in neuroblastomas and patient prognosis. Int J Cancer 1998; 79: 226-31.
185. Mellstrom K, Bjelfman C, Hammerling U, Pahlman S. Expression of c-src in cultured human neuroblastoma and small-cell lung carcinoma cell lines correlates with neurocrine differentiation. Mol Cell Biol 1987; 7: 4178-84.
186. Budde RJ, Ke S, Levin VA. Activity of pp60c-src in 60 different cell lines derived from human tumors. Cancer Biochem Biophys 1994; 14: 171-5.
187. Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, et al. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 2003; 88: 73-9.
188. Barnekow A, Paul E, Schartl M. Expression of the c-src protooncogene in human skin tumors. Cancer Res 1987; 47: 235-40.
189. Loganzo F, Jr., Dosik JS, Zhao Y, Vidal MJ, Narius DM, Sudol M, et al. Elevated expression of protein tyrosine kinase c-Yes, but not c-Src, in human malignant melanoma. Oncogene 1993; 8: 2637-44.
190. Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002; 21: 7001-10.
191. O'Connor TJ, Neufeld E, Bechberger J, Fujita DJ. pp60c-src in human melanocytes and melanoma cells exhibits elevated specific activity and reduced tyrosine 530 phosphorylation compared to human fibroblast pp60c-src. Cell Growth Differ 1992; 3: 435-42.
192. O'Connor TJ, Bjorge JD, Cheng HC, Wang JH, Fujita DJ. Mechanism of c-SRC activation in human melanocytes: elevated level of protein tyrosine phosphatase activity directed against the carboxy-terminal regulatory tyrosine. Cell Growth Differ 1995; 6: 123-30.
193. O'Connor TJ, Fujita DJ. Differentiation of B16 murine melanoma cells is associated with an increased level of c-SRC. Melanoma Res 1995; 5: 5-13.
194. Park J, Meisler AI, Cartwright CA. c-Yes tyrosine kinase activity in human colon carcinoma. Oncogene 1993; 8: 2627-35.
195. Pena SV, Melhem MF, Meisler AI, Cartwright CA. Elevated c-yes tyrosine kinase activity in premalignant lesions of the colon. Gastroenterology 1995; 108: 117-24.
196. Veillette A, Foss FM, Sausville EA, Bolen JB, Rosen N. Expression of the lck tyrosine kinase gene in human colon carcinoma and other non-lymphoid human tumor cell lines. Oncogene Res 1987; 1: 357-74.
197. McCracken S, Kim CS, Xu Y, Minden M, Miyamoto NG. An alternative pathway for expression of p56lck from type I promoter transcripts in colon carcinoma. Oncogene 1997; 15: 2929-37.
198. Nakamura K, Chijiiwa Y, Nawata H. Augmented expression of LCK message directed from the downstream promoter in human colorectal cancer specimens. Eur J Cancer 1996; 32A: 1401-7.
199. Martin GS. The hunting of the Src. Nat Rev Mol Cell Biol 2001; 2: 467-75.
200. Ma YC, Huang XY. Novel regulation and function of Src tyrosine kinase. Cell Mol Life Sci 2002; 59: 456-62.
201. Pellicena P, Miller WT. Coupling kinase activation to substrate recognition in SRC-family tyrosine kinases. Front Biosci 2002; 7: d256-67.
202. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997; 13: 513-609.
203. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
204. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 1995; 375: 577-81.
205. Schlessinger J. New roles for Src kinases in control of cell survival and angiogenesis. Cell 2000; 100: 293-6.
206. Frame MC, Fincham VJ, Carragher NO, Wyke JA. v-Src's hold over actin and cell adhesions. Nat Rev Mol Cell Biol 2002; 3: 233-45.
207. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987; 262: 5592-5.
208. Uehara Y, Hori M, Takeuchi T, Umezawa H. Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. Mol Cell Biol 1986; 6: 2198-206.
209. Nakamura H, Iitaka Y, Imoto M, Isshiki K, Naganawa H, Takeuchi T, et al. The structure of an epidermal growth factor-receptor kinase inhibitor, erbstatin. J Antibiot (Tokyo) 1986; 39: 314-5.
210. Umezawa H, Imoto M, Sawa T, Isshiki K, Matsuda N, Uchida T, et al. Studies on a new epidermal growth factor-receptor kinase inhibitor, erbstatin, produced by MH435-hF3. J Antibiot (Tokyo) 1986; 39: 170-3.
211. Isshiki K, Imoto M, Sawa T, Umezawa K, Takeuchi T, Umezawa H, et al. Inhibition of tyrosine protein kinase by synthetic erbstatin analogs. J Antibiot (Tokyo) 1987; 40: 1209-10.
212. Imoto M, Umezawa K, Komuro K, Sawa T, Takeuchi T, Umezawa H. Antitumor activity of erbstatin, a tyrosine protein kinase inhibitor. Jpn J Cancer Res 1987; 78: 329-32.
213. Uehara Y, Murakami Y, Mizuno S, Kawai S. Inhibition of transforming activity of tyrosine kinase oncogenes by herbimycin A. Virology 1988; 164: 294-8.
214. Yaish P, Gazit A, Gilon C, Levitzki A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 1988; 242: 933-5.
215. Margolis B, Rhee SG, Felder S, Mervic M, Lyall R, Levitzki A, et al. EGF induces tyrosine phosphorylation of phospholipase C-II: a potential mechanism for EGF receptor signaling. Cell 1989; 57: 1101-7.
216. Yoneda T, Lyall RM, Alsina MM, Persons PE, Spada AP, Levitzki A, et al. The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice. Cancer Res 1991; 51: 4430-5.
217. Levitzki A. Tyrosine kinases as targets for cancer therapy. Eur J Cancer 2002; 38: S11-8.
218. Druker BJ. Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy. Eur J Cancer 2002; 38: S70-6.
219. Druker BJ. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene 2002; 21: 8541-6.
220. Manley PW, Cowan-Jacob SW, Buchdunger E, Fabbro D, Fendrich G, Furet P, et al. Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer 2002; 38: S19-27.
221. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289: 1938-42.
222. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem 1996; 271: 695-701.
223. Missbach M, Jeschke M, Feyen J, Muller K, Glatt M, Green J, et al. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone 1999; 24: 437-49.
224. Missbach M, Altmann E, Widler L, Susa M, Buchdunger E, Mett H, et al. Substituted 5,7-diphenyl-pyrrolo[2,3d]pyrimidines: potent inhibitors of the tyrosine kinase c-Src. Bioorg Med Chem Lett 2000; 10: 945-9.
225. Arnold LD, Calderwood DJ, Dixon RW, Johnston DN, Kamens JS, Munschauer R, et al. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I. Bioorg Med Chem Lett 2000; 10: 2167-70.
226. Burchat AF, Calderwood DJ, Hirst GC, Holman NJ, Johnston DN, Munschauer R, et al. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck II. Bioorg Med Chem Lett 2000; 10: 2171-4.
227. Widler L, Green J, Missbach M, Susa M, Altmann E. 7-Alkyl- and 7-cycloalkyl-5-aryl-pyrrolo[2,3-d]pyrimidines - potent inhibitors of the tyrosine kinase c-Src. Bioorg Med Chem Lett 2001; 11: 849-52.
228. Altmann E, Missbach M, Green J, Susa M, Wagenknecht HA, Widler L. 7-Pyrrolidinyl- and 7-piperidinyl-5-aryl-pyrrolo[2,3-d]pyrimidines - potent inhibitors of the tyrosine kinase c-Src. Bioorg Med Chem Lett 2001; 11: 853-6.
229. Hamby JM, Connolly CJ, Schroeder MC, Winters RT, Showalter HD, Panek RL, et al. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J Med Chem 1997; 40: 2296-303.
230. Klutchko SR, Hamby JM, Boschelli DH, Wu Z, Kraker AJ, Amar AM, et al. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. J Med Chem 1998; 41: 3276-92.
231. Kraker AJ, Hartl BG, Amar AM, Barvian MR, Showalter HD, Moore CW. Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol 2000; 60: 885-98.
232. Blake RA, Broome MA, Liu X, Wu J, Gishizky M, Sun L, et al. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling [In Process Citation]. Mol Cell Biol 2000; 20: 9018-27.
233. Thompson AM, Rewcastle GW, Boushelle SL, Hartl BG, Kraker AJ, Lu GH, et al. Synthesis and structure-activity relationships of 7-substituted 3-(2, 6-dichloropherryl)-1,6-naphthyridin-2(1H)-ones as selective inhibitors of pp60(c-src). J Med Chem 2000; 43: 3134-47.
234. Schroeder MC, Hamby JM, Connolly CJ, Grohar PJ, Winters RT, Barvian MR, et al. Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity. J Med Chem 2001; 44: 1915-26.
235. Wang YD, Miller K, Boschelli DH, Ye F, Wu B, Floyd MB, et al. Inhibitors of src tyrosine kinase: the preparation and structure-activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines. Bioorg Med Chem Lett 2000; 10: 2477-80.
236. Boschelli DH, Wang YD, Ye F, Wu B, Zhang N, Dutia M, et al. Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles. J Med Chem 2001; 44: 822-33.
237. Boschelli DH, Ye F, Wang YD, Dutia M, Johnson SL, Wu B, et al. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem 2001; 44: 3965-77.
238. Berger D, Dutia M, Powell D, Wissner A, DeMorin F, Raifeld Y, et al. Substituted 4-anilino-7-phenyl-3-quinolinecarbonitriles as Src kinase inhibitors. Bioorg Med Chem Lett 2002; 12: 2989-92.
239. Berger D, Dutia M, Powell D, Wu B, Wissner A, DeMorin F, et al. 8-Anilinoimidazo[4,5-g]quinoline-7-carbonitriles as Src kinase inhibitors. Bioorg Med Chem Lett 2002; 12: 2761-5.
240. Boschelli DH, Wang DY, Ye F, Yamashita A, Zhang N, Powell D, et al. Inhibition of Src kinase activity by 4-anilino-7-thienyl-3-quinolinecarbonitriles. Bioorg Med Chem Lett 2002; 12: 2011-4.
241. Waltenberger J, Uecker A, Kroll J, Frank H, Mayr U, Bjorge JD, et al. A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling. Circ Res 1999; 85: 12-22.
242. Liu Y, Bishop A, Witucki L, Kraybill B, Shimizu E, Tsien J, et al. Structural basis for selective inhibition of Src family kinases by PP1. Chem Biol 1999; 6: 671-8.
243. Tatton L, Morley GM, Chopra R, Khwaja A. The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases. J Biol Chem 2003; 278: 4847-53.
244. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J 2003; 371: 199-204.
245. He H, Hirokawa Y, Levitzki A, Maruta H. An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies. Cancer J 2000; 6: 243-8.
246. Sorkina T, Huang F, Beguinot L, Sorkin A. Effect of tyrosine kinase inhibitors on clathrin-coated pit recruitment and internalization of epidermal growth factor receptor. J Biol Chem 2002; 277: 27433-41.
247. Zhu X, Kim JL, Newcomb JR, Rose PE, Stover DR, Toledo LM, et al. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure Fold Des 1999; 7: 651-61.
248. Karni R, Mizrachi S, Reiss-Sklan E, Gazit A, Livnah O, Levitzki A. The pp60c-Src inhibitor PP1 is non-competitive against ATP. FEBS Lett 2003; 537: 47-52.
249. Susa M, Luong-Nguyen NH, Crespo J, Maier R, Missbach M, McMaster G. Active recombinant human tyrosine kinase c-Yes: expression in baculovirus system, purification, comparison to c-Src, and inhibition by a c-Src inhibitor. Protein Expr Purif 2000; 19: 99-106.
250. Chen YH, Lu Q, Goodenough DA, Jeansonne B. Nonreceptor tyrosine kinase c-Yes interacts with occludin during tight junction formation in canine kidney epithelial cells. Mol Biol Cell 2002; 13: 1227-37.
251. Olayioye MA, Badache A, Daly JM, Hynes NE. An essential role for Src kinase in ErbB receptor signaling through the MAPK pathway. Exp Cell Res 2001; 267: 81-7.
252. Sedlacek HH. Kinase inhibitors in cancer therapy: a look ahead. Drugs 2000; 59: 435-76.
253. Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene 2002; 21: 8075-88.
254. Capdeville R, Silberman S, Dimitrijevic S. Imatinib: the first 3 years. Eur J Cancer 2002; 38: S77-82.
255. Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003; 63: 375-81.
256. Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, et al. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2002; 62: 5761-9.
257. Sawyer T, Boyce B, Dalgarno D, Iuliucci J. Src inhibitors: genomics to therapeutics. Expert Opin Investig Drugs 2001; 10: 1327-44.
258. Sawyer TK, Bohacek RS, Dalgarno DC, Eyermann CJ, Kawahata N, Metcalf CA 3rd, et al. SRC homology-2 inhibitors: peptidomimetic and nonpeptide. Mini Rev Med Chem 2002; 2: 475-88.
259. Anderson WF, Umar A, Viner JL, Hawk ET. The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm Design 2002; 8(12): 1035-62.
260. Metcalf CA 3rd, van Schravendijk MR, Dalgarno DC, Sawyer TK. Targeting protein kinases for bone disease: discovery and development of Src inhibitors. Curr Pharm Design 2002; 8(23): 2049-75.
261. Warmuth M, Damoiseaux R, Liu Y, Fabbro D, Gray N. SRC family kinases: potential targets for the treatment of human cancer and leukemia. Curr Pharm Design 2003; 9(25): 2043-59.